GlassScriptPhysician profile
Cindy M Jaime
NPI 1568655785
$7,472.49
in general payments reported to CMS, 2019-2025
25 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,075 · 2020: $17.11 · 2022: $158 · 2023: $483 · 2024: $641 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,599.20 | 2019 | |
| Organon LLC | $380.94 | 2023-2025 | Jada System, Nexplanon |
| Abbvie INC. | $372.04 | 2019-2023 | |
| Hologic Sales and Service, LLC | $277.91 | 2024-2025 | Aptima, Fetal Fibronectin Enzyme Immunoassay, Acessa Provu System |
| Mayne Pharma Commercial LLC | $277.50 | 2023-2025 | |
| Astellas Pharma US INC | $233.91 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $203.49 | 2019-2025 | Slynd |
| Sumitomo Pharma America, INC. | $166.36 | 2023 | Myfembree |
| Biogen, INC. | $125.99 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $115.51 | 2024-2025 | Injectafer |
| Millicent US INC | $106.58 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Pfizer INC. | $102.87 | 2024-2025 | |
| Evofem Biosciences, INC. | $94.59 | 2024-2025 | Phexxi, Solosec, Phexx |
| Aspira Women'S Health INC | $77.38 | 2023-2024 | Ova1 |
| Bayer Healthcare Pharmaceuticals INC. | $62.87 | 2019-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $60.95 | 2019-2020 | |
| Coopersurgical, INC. | $53.56 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Lilly USA, LLC | $29.46 | 2025 | Mounjaro, Zepbound |
| Provepharm INC. | $25.85 | 2025 | Bludigo |
| Allergan, INC. | $21.90 | 2019 | |
| Conmed Corporation | $19.80 | 2025 | Airseal |
| Vertical Pharmaceuticals, LLC | $18.17 | 2019 | |
| Meditrina | $16.25 | 2025 | |
| Glaxosmithkline, LLC. | $15.16 | 2019 | |
| Exact Sciences Corporation | $14.25 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Jaime listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.